Scholarlink

Introduction <p>This study aimed to investigate glycaemic control and safety in Chinese adults with type&#xa0;2 diabetes (T2D) receiving fixed-ratio combination of insulin degludec and liraglutide (IDegLira) in real-world clinical practice.</p> Methods <p>The Tianjin Health and Medical Big Data Super Platform was utilised to assess clinical characteristics, glycaemic control, and safety of Chinese adults with T2D receiving IDegLira between March 5, 2022 and June 30, 2024. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to day&#xa0;180. Secondary endpoints included change in HbA1c by baseline characteristics; change in fasting plasma glucose (FPG), postprandial glucose (PPG), and daily insulin dose; and treatment persistence. Exploratory endpoints included hypoglycaemic events and gastrointestinal adverse events (GI AEs).</p> Results <p>Eligible participants were included in the full analysis set and safety analysis set (both <i>n</i> = 12,103), and participants receiving IDegLira for 180&#xa0;days were included in the effectiveness analysis set (<i>n</i> = 3062). The mean (SD) change in HbA1c, FPG, PPG, and insulin dose after 180&#xa0;days from baseline was − 1.08% (1.87, <i>p</i> &lt; 0.001), − 2.34&#xa0;mmol/L (3.61, <i>p</i> &lt; 0.001), − 2.10&#xa0;mmol/L (4.86, <i>p</i> &lt; 0.001), and − 4.95&#xa0;U/day (21.93, <i>p</i> &lt; 0.001), respectively. Subgroup analyses of HbA1c change demonstrated that IDegLira decreased HbA1c significantly, irrespective of prior treatment, age, most baseline HbA1c, daily insulin dose, and fasting C-peptide quartiles. Median treatment persistence duration was 141.67&#xa0;days (95%&#xa0;CI 135.67–146.67). Low percentages of patients reported hypoglycaemia (0.7%) or GI AEs (11.1%).</p> Conclusions <p>IDegLira statistically improved glycaemic control by reducing HbA1c, FPG, and PPG levels in the Chinese population with T2D, with a favourable safety profile.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Improved Glycaemic Control with IDegLira in Chinese Adults with Type 2 Diabetes in Real-World Settings: A Retrospective, Database Cohort Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月18日

查看全文
  • Shanshan Wang,
  • Bei Sun,
  • Dongdong Zhu,
  • Zewei Shen,
  • Xing Zhong,
  • Liming Chen

摘要

Introduction

This study aimed to investigate glycaemic control and safety in Chinese adults with type 2 diabetes (T2D) receiving fixed-ratio combination of insulin degludec and liraglutide (IDegLira) in real-world clinical practice.

Methods

The Tianjin Health and Medical Big Data Super Platform was utilised to assess clinical characteristics, glycaemic control, and safety of Chinese adults with T2D receiving IDegLira between March 5, 2022 and June 30, 2024. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to day 180. Secondary endpoints included change in HbA1c by baseline characteristics; change in fasting plasma glucose (FPG), postprandial glucose (PPG), and daily insulin dose; and treatment persistence. Exploratory endpoints included hypoglycaemic events and gastrointestinal adverse events (GI AEs).

Results

Eligible participants were included in the full analysis set and safety analysis set (both n = 12,103), and participants receiving IDegLira for 180 days were included in the effectiveness analysis set (n = 3062). The mean (SD) change in HbA1c, FPG, PPG, and insulin dose after 180 days from baseline was − 1.08% (1.87, p < 0.001), − 2.34 mmol/L (3.61, p < 0.001), − 2.10 mmol/L (4.86, p < 0.001), and − 4.95 U/day (21.93, p < 0.001), respectively. Subgroup analyses of HbA1c change demonstrated that IDegLira decreased HbA1c significantly, irrespective of prior treatment, age, most baseline HbA1c, daily insulin dose, and fasting C-peptide quartiles. Median treatment persistence duration was 141.67 days (95% CI 135.67–146.67). Low percentages of patients reported hypoglycaemia (0.7%) or GI AEs (11.1%).

Conclusions

IDegLira statistically improved glycaemic control by reducing HbA1c, FPG, and PPG levels in the Chinese population with T2D, with a favourable safety profile.